Zepp Health Corp. 2024 Annual Report (Form 20-F) Summary
Business Context and Reporting Period
Company: Zepp Health Corp. (NYSE: ZEPP)
Reporting Period: Fiscal year ended December 31, 2024
Reporting Currency: U.S. Dollars (changed from Renminbi starting Q2 2024 to better reflect operations)
Business Overview: A global smart wearable and health technology leader operating under brands Amazfit, Zepp Clarity, and Zepp Aura. The company designs, manufactures, and sells smartwatches, bands, rings, and health devices. It operates through a Cayman Islands holding company structure with significant operations in China conducted via Variable Interest Entities (VIEs). As of 2024, VIEs contributed 18.0% of total revenues.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 (US$) | 2023 (US$) | 2022 (US$) |
|---|---|---|---|
| Total Revenues | 182.6 million | 352.9 million | 613.6 million |
| Gross Profit | 70.2 million | 92.4 million | 118.9 million |
| Gross Margin | 38.5% | 26.2% | 19.4% |
| Operating Loss | (47.3) million | (30.5) million | (61.9) million |
| Net Loss | (75.8) million | (31.1) million | (43.3) million |
| Cash & Equivalents | 91.1 million | 133.7 million | 128.6 million |
| Total Debt (Short & Long Term) | 117.1 million | 121.7 million | N/A |
| Operating Cash Flow | (24.4) million | 42.6 million | (117.1) million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 48.3% to $182.6 million. This was primarily driven by an 88.0% decline in sales of Xiaomi Wearable Products (from $92.0M in 2023 to $11.0M in 2024) following the expiration of a strategic cooperation agreement in January 2025. Sales of self-branded Amazfit products also decreased 34.2% due to a limited new product launch cycle in 2024.
- Margin Expansion: Despite lower revenue, gross margin improved significantly to 38.5% (up 12.3 percentage points from 2023), driven by a favorable product mix with higher-margin Amazfit-branded products.
- Increased Net Loss: Net loss widened to $75.8 million from $31.1 million in 2023. This was exacerbated by a $13.7 million income tax expense (primarily valuation allowance for deferred tax assets) and $10.1 million in impairment losses from long-term investments.
- ADS Ratio Change: On September 16, 2024, the company adjusted its ADS ratio from 1 ADS = 4 shares to 1 ADS = 16 shares.
Guidance, Outlook, and Risks
Outlook & Strategy: Management is focusing on brand recognition for Amazfit, expanding international markets (Europe, U.S., Asia), and investing in AI-driven health technologies (Zepp OS 4.0, Zepp Coach). The company intends to retain earnings to fund operations and expansion rather than paying dividends in the near future.
Key Risks & Contingencies:
- VIE Structure: The company relies on contractual arrangements with Chinese VIEs for a portion of its operations. Uncertainty regarding PRC laws could impact the enforceability of these arrangements, potentially affecting control and financial consolidation.
- Customer Concentration: While reliance on Xiaomi has decreased, the company remains exposed to the loss of key customers. The strategic cooperation agreement with Xiaomi expired in January 2025.
- Regulatory & Geopolitical: Risks include PRC data security regulations, potential delisting under the Holding Foreign Companies Accountable Act (HFCAA) if PCAOB inspections are restricted, and U.S.-China trade tensions/tariffs.
- Listing Compliance: The company previously received notice regarding NYSE minimum price requirements but regained compliance in October 2024. Continued volatility poses a delisting risk.
- PFIC Status: The company believes it is a Passive Foreign Investment Company (PFIC) for U.S. tax purposes, which may have adverse tax consequences for U.S. investors.
Investor Verification Checklist
- Xiaomi Relationship: Verify the status of the renewed or new strategic cooperation agreement with Xiaomi following the expiration of the 2023 agreement in January 2025.
- Product Pipeline: Assess the market reception of the Amazfit T-Rex 3 and upcoming 2025 product launches (e.g., Amazfit Active 2, Bip 6) to determine if revenue decline is a temporary cycle or structural shift.
- Investment Impairments: Review the specific details of the $10.1 million impairment loss on long-term investments and the performance of equity method investments (e.g., Jiangsu Yitong).
- Cash Position: Monitor the burn rate given the negative operating cash flow of $24.4 million and the reduction in cash reserves to $91.1 million.
- Regulatory Filings: Confirm ongoing compliance with NYSE listing standards and monitor any updates regarding PCAOB inspection access in China.